CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind ImmunityBio Investors of a Lead Plaintiff Deadline of August 29, 2023

NEW YORK, Aug. 7, 2023

The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between May 23, 2022 and May 10, 2023.

If you suffered a loss on your investment in ImmunityBio, contact us about potential recovery by using the link below. There is no cost or obligation to you.

https://www.wongesq.com/pslra-1/immunitybio-class-action-submission-form?prid=43020&wire=4

ABOUT THE ACTION: The class action against ImmunityBio includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) ImmunityBio conducted insufficient due diligence to discover, or else did discover and ignored, Good Manufacturing Practice ("GMP") deficiencies at its third-party contract manufacturing organizations ("CMOs") for the antibody cytokine fusion protein N-803, commercially referred to as "Anktiva"; (ii) one or more of the Company's third-party CMOs for Anktiva did in fact suffer from GMP deficiencies; (iii) the foregoing deficiencies was likely to cause the FDA to reject the Anktiva Biologics License Application ("BLA") in its present form; (iv) accordingly, the Company overstated the regulatory approval prospects for the Anktiva BLA; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

DEADLINE: August 29, 2023

Aggrieved ImmunityBio investors only have until August 29, 2023 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.